Foghorn Therapeutics Inc. Operating Lease Cost
Foghorn Therapeutics Inc. (FHTX) reported Operating Lease Cost of $1.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Foghorn Therapeutics Inc. operating lease, cost for the quarter ending 2026-06-30 was $1.28M, a 31.69% decline year-over-year.
- Foghorn Therapeutics Inc. operating lease, cost for the quarter ending 2026-03-31 was $1.28M, a 33.49% decline year-over-year.
- Foghorn Therapeutics Inc. operating lease, cost for the quarter ending 2025-12-31 was $1.15M, a 40.58% decline year-over-year.
- Foghorn Therapeutics Inc. operating lease, cost for the quarter ending 2025-09-30 was $1.09M, a 44.57% decline year-over-year.
- Foghorn Therapeutics Inc. operating lease, cost for fiscal 2025 was $6.06M, a 23.49% decline from fiscal 2024.
- Foghorn Therapeutics Inc. operating lease, cost for fiscal 2024 was $7.92M, a 2.76% increase from fiscal 2023.
- Foghorn Therapeutics Inc. operating lease, cost for fiscal 2023 was $7.71M, a 2.34% increase from fiscal 2022.
- Foghorn Therapeutics Inc. operating lease, cost for fiscal 2022 was $7.53M, a 0.20% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.28M 10-Q · filed 2026-08-06 | $2.57M 10-Q · filed 2026-08-06 | $3.72M derived: sum of 3 quarters · filed 2026-08-06 | $4.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.28M 10-Q · filed 2026-05-07 | $2.44M derived: sum of 2 quarters · filed 2026-05-07 | $3.53M derived: sum of 3 quarters · filed 2026-05-07 | $5.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $2.25M derived: sum of 2 quarters · filed 2026-03-11 | $4.13M derived: sum of 3 quarters · filed 2026-08-06 | $6.06M 10-K · filed 2026-03-11 |
| 2025-09-30 | $1.09M 10-Q · filed 2025-11-05 | $2.97M derived: sum of 2 quarters · filed 2026-08-06 | $4.91M 10-Q · filed 2025-11-05 | $6.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.88M 10-Q · filed 2026-08-06 | $3.81M 10-Q · filed 2026-08-06 | $5.75M derived: sum of 3 quarters · filed 2026-08-06 | $7.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.93M 10-Q · filed 2026-05-07 | $3.87M derived: sum of 2 quarters · filed 2026-05-07 | $5.85M derived: sum of 3 quarters · filed 2026-05-07 | $7.85M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.91M derived: sum of 2 quarters · filed 2026-03-11 | $5.92M derived: sum of 3 quarters · filed 2026-03-11 | $7.92M 10-K · filed 2026-03-11 |
| 2024-09-30 | $1.97M 10-Q · filed 2025-11-05 | $3.98M derived: sum of 2 quarters · filed 2025-11-05 | $5.98M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $2.01M 10-Q · filed 2025-08-05 | $4.01M 10-Q · filed 2025-08-05 | ||
| 2023-12-31 | $7.71M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $7.53M 10-K · filed 2024-03-07 | |||
| 2021-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.77M derived: sum of 2 quarters · filed 2023-03-09 | $5.66M derived: sum of 3 quarters · filed 2023-03-09 | $7.55M 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.89M 10-Q · filed 2021-11-09 | $3.77M derived: sum of 2 quarters · filed 2021-11-09 | $5.66M 10-Q · filed 2021-11-09 | $7.55M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $1.89M 10-Q · filed 2021-08-10 | $3.77M 10-Q · filed 2021-08-10 | $5.66M derived: sum of 3 quarters · filed 2022-08-09 | $7.82M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.89M 10-Q · filed 2021-05-11 | $3.77M derived: sum of 2 quarters · filed 2022-08-09 | $5.94M derived: sum of 3 quarters · filed 2022-08-09 | $7.66M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $1.89M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $4.05M derived: sum of 2 quarters · filed 2022-08-09 | $5.77M derived: sum of 3 quarters · filed 2022-08-09 | $7.03M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $2.16M 10-Q · filed 2021-11-09 | $3.89M derived: sum of 2 quarters · filed 2021-11-09 | $5.14M 10-Q · filed 2021-11-09 | $5.50M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $1.73M 10-Q · filed 2021-08-10 | $2.98M 10-Q · filed 2021-08-10 | $3.34M derived: sum of 3 quarters · filed 2021-08-10 | $3.78M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $1.26M 10-Q · filed 2021-05-11 | $1.61M derived: sum of 2 quarters · filed 2021-05-11 | $2.06M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $353.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $798.00K derived: sum of 2 quarters · filed 2021-03-18 | $1.67M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $445.00K 10-Q · filed 2020-12-04 | $1.32M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |